ANI Pharmaceuticals reported record second-quarter 2026 revenues of $266 million, a 26% year-over-year increase, driven by strong performance in rare disease and generics. Record Cortrophin Gel revenues reached $117.1 million, up 43% year-over-year and 56% sequentially, while the generics business delivered $99.1 million, up 10% year-over-year. Adjusted EBITDA hit a record $71.6 million, up 32% year-over-year, and the company reaffirmed full-year 2026 guidance for total revenue of $1.08 billion to $1.14 billion and adjusted EBITDA of $285 million to $300 million. Cortrophin Gel full-year guidance was modestly revised to $520 million to $540 million, reflecting first-half results, though back-half expectations remain largely intact. The company completed a 50% expansion of its rare disease sales force to approximately 180 representatives, with strong early demand from the gout launch, as over 95% of new reps generated multiple new cases.
ANI Pharmaceuticals IncRecord Q2 revenue and EBITDA beat, with reaffirmed guidance.
